CMPS - Atai Life Sciences upgraded at Maxim on Beckley investment
2024-04-03 10:47:15 ET
More on ATAI Life Sciences
- De-Risking Psychedelics: Compass Pathways, Cybin And Atai
- Psychedelic stocks gain after FDA priority review for MDMA therapy
- Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18%
- Seeking Alpha’s Quant Rating on ATAI Life Sciences
- Historical earnings data for ATAI Life Sciences